Richard David Boyce

Richard David Boyce

Auto-generated profile, based on publicly available information

Richard David Boyce

Department of Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2015 in Drug Safety
Verified
Journal Article
Closed access
PDF file
RSRichard T. Scheife
Richard T. Scheife
LHLisa E. Hines
Lisa E. Hines
RBRichard D. Boyce
Richard D. Boyce
SCSophie P. Chung
Sophie P. Chung
JMJeremiah D. Momper
Jeremiah D. Momper
DMDaniel C Malone
Daniel C Malone

1 June 2015 in Journal of Biomedical Informatics
Verified
Journal Article
Open access
SASerkan Ayvaz
Serkan Ayvaz
JHJohn Horn
John Horn
OHOktie Hassanzadeh
Oktie Hassanzadeh
QZQian Zhu
Qian Zhu
JSJohann Stan
Johann Stan
RBRichard D. Boyce
Richard D. Boyce
Although potential drug-drug interactions (PDDIs) are a significant source of preventable drug-related harm, there is currently no single complete source of PDDI information. In the current study, all publically available sources of PDDI information that could be identified using a comprehensive and broad search were combined into a single dataset. The combined dataset merged fourteen different sources including 5 clinically-oriented information sources, 4 Natural Language Processing (NLP) Corpora, and 5 Bioinformatics/Pharmacovigilance information sources. As a comprehensive PDDI source, the merged dataset might benefit the pharmacovigilance text mining community by making it possible to compare the representativeness of NLP corpora for PDDI text extraction tasks, and specifying elements that can be useful for future PDDI extraction purposes. An analysis of the overlap between and across the data sources showed that there was little overlap. Even comprehensive PDDI lists such as DrugBank, KEGG, and the NDF-RT had less than 50% overlap with each other. Moreover, all of the comprehensive lists had incomplete coverage of two data sources that focus on PDDIs of interest in most clinical settings. Based on this information, we think that systems that provide access to the comprehensive lists, such as APIs into RxNorm, should be careful to inform users that the lists may be incomplete with respect to PDDIs that drug experts suggest clinicians be aware of. In spite of the low degree of overlap, several dozen cases were identified where PDDI information provided in drug product labeling might be augmented by the merged dataset. Moreover, the combined dataset was also shown to improve the performance of an existing PDDI NLP pipeline and a recently published PDDI pharmacovigilance protocol. Future work will focus on improvement of the methods for mapping between PDDI information sources, identifying methods to improve the use of the merged dataset in PDDI NLP algorithms, integrating high-quality PDDI information from the merged dataset into Wikidata, and making the combined dataset accessible as Semantic Web Linked Data.

1 February 2017 in Journal of Biomedical Informatics
Verified
Journal Article
Closed access
EVErica A Voss
Erica A Voss
RBR.D. Boyce
R.D. Boyce
PRP.B. Ryan
P.B. Ryan
JLJ. van der Lei
J. van der Lei
PRP.R. Rijnbeek
P.R. Rijnbeek
MSM.J. Schuemie
M.J. Schuemie

14 May 2009 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
RBRichard Boyce
Richard Boyce
PCParmit Chilana
Parmit Chilana
TRTimothy Rose
Timothy Rose
PCR amplification using COnsensus DEgenerate Hybrid Oligonucleotide Primers (CODEHOPs) has proven to be highly effective for identifying unknown pathogens and characterizing novel genes. We describe iCODEHOP; a new interactive web application that simplifies the process of designing and selecting CODEHOPs from multiply-aligned protein sequences. iCODEHOP intelligently guides the user through the degenerate primer design process including uploading sequences, creating a multiple alignment, deriving CODEHOPs and calculating their annealing temperatures. The user can quickly scan over an entire set of degenerate primers designed by the program to assess their relative quality and select individual primers for further analysis. The program displays phylogenetic information for input sequences and allows the user to easily design new primers from selected sequence sub-clades. It also allows the user to bias primer design to favor specific clades or sequences using sequence weights. iCODEHOP is freely available to all interested researchers at https://icodehop.cphi.washington.edu/i-codehop-context/Welcome.

20 October 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MSMatthias Samwald
Matthias Samwald
HXHong Xu
Hong Xu
KBKathrin Blagec
Kathrin Blagec
PEPhilip Empey
Philip Empey
DMDaniel C Malone
Daniel C Malone
RBRichard D Boyce
Richard D Boyce
Pre-emptive pharmacogenomic (PGx) testing of a panel of genes may be easier to implement and more cost-effective than reactive pharmacogenomic testing if a sufficient number of medications are covered by a single test and future medication exposure can be anticipated. We analysed the incidence of exposure of individual patients in the United States to multiple drugs for which pharmacogenomic guidelines are available (PGx drugs) within a selected four-year period (2009–2012) in order to identify and quantify the incidence of pharmacotherapy in a nation-wide patient population that could be impacted by pre-emptive PGx testing based on currently available clinical guidelines. In total, 73 024 095 patient records from private insurance, Medicare Supplemental and Medicaid were included. Patients enrolled in Medicare Supplemental age > = 65 or Medicaid age 40–64 had the highest incidence of PGx drug use, with approximately half of the patients receiving at least one PGx drug during the 4 year period and one fourth to one third of patients receiving two or more PGx drugs. These data suggest that exposure to multiple PGx drugs is common and that it may be beneficial to implement wide-scale pre-emptive genomic testing. Future work should therefore concentrate on investigating the cost-effectiveness of multiplexed pre-emptive testing strategies.

6 August 2020 in Journal of Medical Internet Research
Verified
Journal Article
Open access
JCJhon Camacho
Jhon Camacho
MZManuela Zanoletti-Mannello
Manuela Zanoletti-Mannello
ZLZach Landis-Lewis
Zach Landis-Lewis
SKSandra Kane-Gill
Sandra Kane-Gill
RBRichard D Boyce
Richard D Boyce
Background: The implementation of clinical decision support systems (CDSSs) as an intervention to foster clinical practice change is affected by many factors. Key factors include those associated with behavioral change and those associated with technology acceptance. However, the literature regarding these subjects is fragmented and originates from two traditionally separate disciplines: implementation science and technology acceptance. Objective: Our objective is to propose an integrated framework that bridges the gap between the behavioral change and technology acceptance aspects of the implementation of CDSSs. Methods: We employed an iterative process to map constructs from four contributing frameworks—the Theoretical Domains Framework (TDF); the Consolidated Framework for Implementation Research (CFIR); the Human, Organization, and Technology-fit framework (HOT-fit); and the Unified Theory of Acceptance and Use of Technology (UTAUT)—and the findings of 10 literature reviews, identified through a systematic review of reviews approach. Results: The resulting framework comprises 22 domains: agreement with the decision algorithm; attitudes; behavioral regulation; beliefs about capabilities; beliefs about consequences; contingencies; demographic characteristics; effort expectancy; emotions; environmental context and resources; goals; intentions; intervention characteristics; knowledge; memory, attention, and decision processes; patient–health professional relationship; patient’s preferences; performance expectancy; role and identity; skills, ability, and competence; social influences; and system quality. We demonstrate the use of the framework providing examples from two research projects. Conclusions: We proposed BEAR (BEhavior and Acceptance fRamework), an integrated framework that bridges the gap between behavioral change and technology acceptance, thereby widening the view established by current models.